Gastrointestinal cancers

Recommended treatments for these cancers commonly cause CINV¹¹

Highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) regimens including agents such as
- Cisplatin
- Epirubicin
- 5-FU
Multiday regimens resulting in overlapping periods of acute and delayed CINV
Surgery resulting in comorbid conditions interfering with CINV treatments
Chemotherapy in combination with radiation therapy, potentiating CINV effects

Specific issues underscore the need for a simple and effective option to prevent CINV

Oral mucositis	Mucositis occurs in approximately 40% of cancer patients receiving chemotherapy⁸ 5-FU, while not being highly emetogenic, is highly toxic to mucous membranes, causing mucositis⁸
Loss of appetite	Surgery to remove the tumor, combined with chemotherapy, may cause patients to lose their appetite Patients may be unable to absorb food and medications orally Not getting the proper nutrition due to appetite loss can cause dehydration and fatigue
A high incidence of CINV	Cisplatin carries a greater than 90% risk of developing CINV¹⁰ There is greater than 65% risk of developing delayed CINV with cisplatin¹⁰

SANCUSO is the right choice

Successfully studied in gastrointestinal cancers in a phase III trial²
Helps to avoid CINV caused by MEC and HEC regimens, especially those with cisplatin¹
Provides continuous coverage with one application, so adherence to treatment is not an issue¹
Avoids doubt about GI absorption

IMPORTANT SAFETY INFORMATION
SANCUSO^® (Granisetron Transdermal System) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.¹ SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the patch.¹ Granisetron may mask a progressive ileus and/or gastric distention caused by the underlying condition.¹ Mild application site reactions have occurred; remove the patch if severe reaction or a generalized skin reaction occurs.¹ Patients should avoid direct exposure of application site to natural or artificial sunlight by covering with clothing while wearing the patch and for 10 days after removing it.¹ The most common adverse reaction in patients receiving SANCUSO is constipation (5.4%).¹ SANCUSO contains granisetron.¹ Healthcare professionals should avoid prescribing any additional products that contain granisetron. No clinically relevant drug interactions have been reported in clinical studies with SANCUSO.¹

Gastrointestinal cancers

Recommended treatments for these cancers commonly cause CINV11

Specific issues underscore the need for a simple and effective option to prevent CINV

Oral mucositis

Loss of appetite

A high incidence of CINV

SANCUSO is the right choice

Recommended treatments for these cancers commonly cause CINV¹¹